6. Parkinson disease
2,123 clinical trials,   2,046 drugs   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways

Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03652870
(ClinicalTrials.gov)
November 1, 20198/8/2018Antidepressants Trial in Parkinson's DiseaseA Randomised Placebo-Controlled Trial of Escitalopram and Nortriptyline With Standard Psychological Care for Depression in Parkinson's DiseaseDepression;Parkinson DiseaseDrug: Nortriptyline;Drug: Escitalopram;Drug: PlaceboUniversity College, LondonLondon North West Healthcare NHS Trust;King's College London;University Hospital Plymouth NHS Trust;NHS LothianNot yet recruiting18 Years85 YearsAll408Phase 3NULL
2EUCTR2018-002942-35-GB
(EUCTR)
31/10/201905/09/2019A Randomised Controlled Trial of Escitalopram and Nortriptyline compared with placebo, and standard psychological care, for depression in Parkinson’s diseaseA Randomised Controlled Trial of Escitalopram and Nortriptyline compared with placebo and standard psychological care for depression in Parkinson’s Disease - Antidepressants Trial in Parkinson's Disease (ADepT-PD) Depression in Parkinson's disease
MedDRA version: 20.0;Level: PT;Classification code 10012378;Term: Depression;System Organ Class: 10037175 - Psychiatric disorders
MedDRA version: 20.0;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Escitalopram
INN or Proposed INN: Escitalopram oxalate
Trade Name: Nortriptyline
Product Name: Nortriptyline
INN or Proposed INN: Nortriptyline hydrochloride
University College London Comprehensive Clinical Trials UnitNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
408Phase 3United Kingdom
3EUCTR2007-004009-93-IT
(EUCTR)
20/05/200814/07/2008Prevalence of depression,anxiety and impulse control disorder (ICD) in patients with Parkinson's disease and effectiveness of escitalopramPrevalence of depression,anxiety and impulse control disorder (ICD) in patients with Parkinson's disease and effectiveness of escitalopram Depression, anxiety and ICD
MedDRA version: 14.1;Level: SOC;Classification code 10037175;Term: Psychiatric disorders;System Organ Class: 10037175 - Psychiatric disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: CIPRALEX
INN or Proposed INN: Escitalopram
Trade Name: CIPRALEX
INN or Proposed INN: Escitalopram
LUNDBECK ITALIANULLNot RecruitingFemale: yes
Male: yes
Italy
4NCT00070941
(ClinicalTrials.gov)
July 20039/10/2003SAM-e for the Treatment of Depression in Patients With Parkinson's DiseaseSAM-e Treatment of Depression in Parkinson's Disease.Parkinson's Disease;DepressionDrug: SAM-e;Drug: oral escitalopram;Drug: placeboNew York University School of MedicineNational Center for Complementary and Integrative Health (NCCIH);Office of Dietary Supplements (ODS)Completed30 Years80 YearsAll29Phase 2;Phase 3United States